Sugi Predict

Sugi Predict / Compounds / SCHEMBL1782823

SCHEMBL1782823

SCHEMBL1782823

CC(=O)/C=C/c1ccccc1Br

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 1/20 0.71
▸ LMNA P02545 3/20 0.63
▸ MAPT P10636 3/20 0.63
▸ LY96 Q9Y6Y9 1/20 0.58
▸ KDM4E B2RXH2 2/20 0.58
▸ BCHE P06276 1/20 0.56
▸ IAPP P10997 1/20 0.55
▸ GLA P06280 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53
▸ KMT2A Q03164 3/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ USP2 O75604 1/20 0.48
▸ ATM Q13315 3/20 0.48
▸ RELA Q04206 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.43
▸ HSP90AA1 P07900 1/20 0.43
▸ NFE2L2 Q16236 2/20 0.42
▸ NFKB1 P19838 2/20 0.42
▸ JUN P05412 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30963013 1.00 HSD11B1 (0.71) HSD11B1LMNAMAPTLY96KDM4E
SCHEMBL1782824 1.00 HSD11B1 (0.71) HSD11B1LMNAMAPTLY96KDM4E
SCHEMBL14441077 0.85 MAPT (0.76) HSD11B1LMNAMAPTKDM4EBCHE
SCHEMBL17973990 0.83 HSD11B1 (1.00) HSD11B1LMNAMAPTLY96KDM4E
SCHEMBL30317482 0.83 HSD11B1 (1.00) HSD11B1LMNAMAPTLY96KDM4E
SCHEMBL1049718 0.82 HSD11B1 (0.74) HSD11B1MAPTLY96KDM4EBCHE
SCHEMBL1049717 0.82 HSD11B1 (0.74) HSD11B1MAPTLY96KDM4EBCHE
SCHEMBL1479962 0.80 HSD11B1 (0.71) HSD11B1LMNAMAPTLY96BCHE
SCHEMBL1479957 0.80 HSD11B1 (0.71) HSD11B1LMNAMAPTLY96BCHE
SCHEMBL9780865 0.80 HSD11B1 (0.71) HSD11B1LMNAMAPTLY96BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180127418-A1 HETEROCYCLES USEFUL AS IDO AND TDO INHIBITORS HANGZHOU INNOGATE PHARMA CO., LTD. (CN) 2018-05-10 — — US disclosed
US-9540299-B2 MTOR-independent activator of TFEB for autophagy enhancement and uses thereof HONG KONG BAPTIST UNIVERSITY (HK) 2017-01-10 — — US disclosed
US-9540299-B2 MTOR-independent activator of TFEB for autophagy enhancement and uses thereof HONG KONG BAPTIST UNIVERSITY (HK) 2017-01-10 — — US disclosed
US-20160221907-A1 MTOR-independent activator of TFEB for autophagy enhancement and uses thereof HONG KONG BAPTIST UNIVERSITY (CN) 2016-08-04 — — US disclosed
US-20160221907-A1 MTOR-independent activator of TFEB for autophagy enhancement and uses thereof HONG KONG BAPTIST UNIVERSITY (CN) 2016-08-04 — — US disclosed
US-8592430-B2 Quinazolin-oxime derivatives as Hsp90 inhibitors DAC SLR (IT) 2013-11-26 — — US disclosed
EP-2144889-B1 QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS DAC SRL (IT) 2012-08-29 — — EP disclosed
EP-2144889-B1 QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS DAC SRL (IT) 2012-08-29 — — EP disclosed
US-20110118258-A1 QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS DAC SRL (IT) 2011-05-19 — — US disclosed
US-20110118258-A1 QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS DAC SRL (IT) 2011-05-19 — — US disclosed
US-20110118258-A1 QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS DAC SRL (IT) 2011-05-19 — — US disclosed
EP-2144889-A2 QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS DAC S.r.l. (IT) 2010-01-20 — — EP disclosed
WO-2008142720-A2 QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS DAC SRL (IT) 2008-11-27 — — WO disclosed
WO-2008142720-A2 QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS DAC SRL (IT) 2008-11-27 — — WO disclosed
EP-1885701-A2 2-AMINO-QUINAZ0LIN-5-ONES AS HSP90 INHIBITORS USEFUL IN TREATING PROLIFERATION DISEASES Novartis Vaccines and Diagnostics, Inc. (US) 2008-02-13 — — EP disclosed
US-7291743-B2 Isoxazole derivatives and methods of treating nitric oxide mediated diseases GENEBLUE CORPORATION (US) 2007-11-06 — — US disclosed
US-20070027150-A1 2-Amino-quinazolin-5-ones NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2007-02-01 — — US disclosed
US-20070027150-A1 2-Amino-quinazolin-5-ones NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2007-02-01 — — US disclosed
US-20070027150-A1 2-Amino-quinazolin-5-ones NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2007-02-01 — — US disclosed
WO-2006113498-A2 2-AMINO-QUINAZ0LIN-5-ONES AS HSP90 INHIBITORS USEFUL IN TREATING PROLIFERATION DISEASES NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) 2006-10-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180127418-A1 HETEROCYCLES USEFUL AS IDO AND TDO INHIBITORS IDO1, IDO2, TDO2 HSD11B1 771/4885LMNA 4322/4885MAPT 2085/4885
US-20110118258-A1 QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 HSD11B1 700/4885LMNA 4565/4885MAPT 296/4885
US-20160221907-A1 MTOR-independent activator of TFEB for autophagy enhancement and uses thereof TFEB, SQSTM1, ATG7 HSD11B1 4798/4885LMNA 2770/4885MAPT 388/4885
US-20070027150-A1 2-Amino-quinazolin-5-ones TK1, TK2, SLC1A5 HSD11B1 1628/4885LMNA 1618/4885MAPT 457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.